Citicoline eye drops for preserving vision in glaucoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy of 2% citicoline eye drops in reducing visual field deterioration in patients with progressing open-angle glaucoma (OAG). The study aims to assess not only the preservation of visual fields but also the impact of citicoline on structural changes in the eye, measured using Spectral Domain Optical Coherence Tomography (SD-OCT). Additionally, the safety profile of citicoline eye drops will be evaluated. Participants will receive either the citicoline treatment or a placebo, allowing for a comparison of outcomes between the two groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed written informed consent.
2. Age ≥ 18 years.
3. Eyes with OAG, Pseudoexfoliation and pigmentary glaucoma will be included.
4. Best Corrected Visual Acuity (BCVA) ≥ 0.5 for the study eye.
5. Controlled IOP (≤ 18 mmHg, average of the last 3 measurements in the clinic) in the study eye.
6. Visual field MD not worse than -12 dB at the latest assessment in the clinic for the study eye.
7. Deteriorating MD at a rate between -0.5 dB/year and -1.0 dB/year, estimated from the latest VF tests collected in the clinic (at least 4) over a period during which incisional glaucoma surgery was not performed. Combinations of SITA Standard and Fast strategies (but not SITA Faster) is admissible. Patients who reach the desired minimum number of tests (4) with a mixture of SITA Standard/Fast and SITA Faster tests will need to perform additional replacement tests according to the prevalent strategy used in their series of VF (i.e. additional SITA Standard/Fast tests if ≤ 2 tests were SITA Faster; additional SITA Faster if \> 2 tests were SITA Faster).
8. Glaucoma definition will be based on VF damage (24-2, any SITA strategy) and spatially congruent glaucomatous changes at the ONH. If both eyes are eligible, the eye with the better MD will be chosen as the study eye.
9. Women of childbearing potential willing to use an appropriate method of contraception.

Exclusion Criteria:

1. Cataract in the study eye which, in the opinion of the clinician, may require cataract surgery within the next three years.
2. Only-eye patients (visual acuity \< 0.1 decimals in one eye or more than two paracentral VF locations with a sensitivity of \< 10 dB).
3. Known intolerance or allergy to any of the components in the eye drops.
4. Diode laser treatment or glaucoma surgery in the past 2 years or cataract surgery within the last 6 months in the study eye.
5. Eyes with any type of glaucoma other than primary, pseudoexfoliative or pigmentary OAG.
6. Patients with other ocular or systemic comorbidities that, in the opinion of the Investigator, might affect the VF or the execution of the test.
7. Patients already on topical or systemic citicoline treatment.
8. Patients taking other systemic or topical potential neuroprotectors competing with citicoline eye drops 2% (a list will be provided) unwilling to suspend these treatments and undergo a washout period of 6 months prior to the study.
9. Patients unable to perform reliable VF tests, based on the assessment of the last 4 available 24-2 Humphrey Field Analyzer (HFA) VF tests performed in the clinic with a false positive rate (FP) ≤ 15%.
10. Pregnant and nursing patients.

Where it's running

• Presidio Ospedale San Paolo
  Milan, Mi, Italy Recruiting

Study contacts

• Study coordinator: Carla Russo
• Email: c.russo@omikronitalia.it
• Phone: +39 06 80693572

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Slow-coagulation trans-scleral cyclophotocoagulation versus trabeculectomy with mitomycin C for uncontrolled open-angle glaucoma after cataract surgery

  This trial will test whether slow-coagulation trans-scleral cyclophotocoagulation or trabeculectomy with mitomycin C better lowers eye pressure in people over 40 with pseudophakic open-angle glaucoma not controlled by medications.

  Recruiting Minia University · Minya · NCT07152132

• Virtual reality visual field testing for people with open-angle glaucoma

  This will test whether a virtual reality visual field test can match the standard Humphrey Field Analyzer for people with open‑angle glaucoma.

  Recruiting Nova Scotia Health Authority · Halifax, Nova Scotia · NCT07063537

• Evaluating the safety and effectiveness of iDose TR with cataract surgery

  This study is testing if adding the iDose TR implant during cataract surgery can safely lower eye pressure better than just having cataract surgery alone for people with glaucoma or high eye pressure.

  Recruiting Phase 4 Glaukos Corporation · Kenosha, Wisconsin · NCT06848946

• Electrical stimulation to improve vision in glaucoma

  This trial will test whether a noninvasive transorbital alternating current stimulation device (EYETRONIC rtACS) can improve vision in adults with moderate open-angle glaucoma.

  Recruiting Stanford University · Palo Alto, California · NCT06685211

• Comparing Hydrus Microstent and Goniotomy for Glaucoma Treatment

  This study is testing whether the Hydrus Microstent works better than goniotomy for lowering eye pressure in people with mild to moderate glaucoma who are also having cataract surgery.

  Recruiting Massachusetts Eye and Ear Infirmary · Boston, Massachusetts · NCT06289491

• Comparing two treatments for glaucoma with cataract

  This study is testing whether a new surgery for glaucoma combined with cataract removal works as well as the usual surgery plus eye drops for people with both conditions.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT06201455

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.